Vernakalant: Pharmacology, electrophysiology, safety and efficacy

Gerald V. Naccarelli, Deborah L. Wolbrette, Soraya Samii, Javier E. Banchs, Erica Penny-Peterson, Robert Stevenson, Mario D. Gonzalez

Research output: Contribution to journalReview article

12 Scopus citations

Abstract

The development of new antiarrhythmic agents for the treatment of atrial fibrillation is advancing simultaneously on several fronts. The molecular structure of existing agents such as amiodarone is being modified in an attempt to improve safety and reduce adverse effects. Similarly, atrial-selective antiarrhythmic drugs are being developed to minimize the occurrence of ventricular proarrhythmia. One of these atrial-selective compounds is vernakalant, which has demonstrated efficacy in terminating atrial fibrillation when given intravenously. In addition, preliminary data suggest that it could also suppress recurrences when used orally. This paper reviews the pharmacology, electrophysiology, efficacy and safety of intravenous and oral vernakalant.

Original languageEnglish (US)
Pages (from-to)325-329
Number of pages5
JournalDrugs of Today
Volume44
Issue number5
DOIs
StatePublished - May 1 2008

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this